| 8 Aug 2025 | 07:00:02 | Cancellation - Celadon Pharmaceuticals Plc |
| 5 Aug 2025 | 18:00:00 | Celadon Pharmaceuticals |
| 28 Jul 2025 | 16:10:33 | Result of General Meeting |
| 2 Jul 2025 | 07:00:06 | Proposed Cancellation |
| 1 Jul 2025 | 11:48:57 | Funding Update |
| 8 Aug 2025 | 07:00:02 | Cancellation - Celadon Pharmaceuticals Plc |
| 5 Aug 2025 | 18:00:00 | Celadon Pharmaceuticals |
| 28 Jul 2025 | 16:10:33 | Result of General Meeting |
| 2 Jul 2025 | 07:00:06 | Proposed Cancellation |
| 1 Jul 2025 | 11:48:57 | Funding Update |
| 20 May 2026 | Annual Report and Accounts (to 2024-12-31) |
Celadon Pharmaceuticals PLC is a UK-based pharmaceutical company focused on the development, production, and supply of cannabis-based medicines aimed at addressing unmet clinical needs. The company operates an indoor hydroponic cultivation facility, producing high-THC cannabis products that comply with UK regulations. Celadon develops proprietary Active Pharmaceutical Ingredients (APIs) and engages in strategic partnerships to enhance its capabilities and expand its market reach, particularly in the areas of chronic pain and women's health.
| 8 Aug 2025 | 07:00:02 | Cancellation - Celadon Pharmaceuticals Plc |
| 5 Aug 2025 | 18:00:00 | Celadon Pharmaceuticals |
| 28 Jul 2025 | 16:10:33 | Result of General Meeting |
| 2 Jul 2025 | 07:00:06 | Proposed Cancellation |
| 1 Jul 2025 | 11:48:57 | Funding Update |
| 20 May 2026 | Annual Report and Accounts (to 2024-12-31) |
Celadon Pharmaceuticals PLC is a UK-based pharmaceutical company focused on the development, production, and supply of cannabis-based medicines aimed at addressing unmet clinical needs. The company operates an indoor hydroponic cultivation facility, producing high-THC cannabis products that comply with UK regulations. Celadon develops proprietary Active Pharmaceutical Ingredients (APIs) and engages in strategic partnerships to enhance its capabilities and expand its market reach, particularly in the areas of chronic pain and women's health.